Hoskins J M, Shenfield G M, Gross A S
Department of Clinical Pharmacology, Royal North Shore Hospital, St Leonards, NSW, Australia.
Br J Clin Pharmacol. 1998 Nov;46(5):499-504. doi: 10.1046/j.1365-2125.1998.00807.x.
To investigate the relationship between proguanil metabolic ratio (MR, proguanil/cycloguanil) and CYP2C19 genotype in a Caucasian population.
Ninety-nine Caucasians (age range: 18-55 years, 54 female, 45 male) were genotyped for CYP2C19 and phenotyped for proguanil oxidation by collecting urine for 8 h after taking 100 mg proguanil hydrochloride. Proguanil and cycloguanil concentrations were measured by h.p.l.c. PCR was employed for CYP2C19 genotyping.
The three (3%) individuals who were homozygous for CYP2C19*2 (*2/*2) had the highest proguanil MRs (range: 8.0-134.6). Seventy-three (74%) individuals were homozygous for the wild-type allele (*1/*1) and 23 (23%) were heterozygous (*1/*2). The *1/*1 individuals had lower MRs (median=1.4, range: 0.23-5.9, P=0.003, Mann-Whitney U-test) than the *1/*2 subjects (median=2.5, range: 0.88-7.3).
A CYP2C19 gene-dose effect for proguanil oxidation to cycloguanil was observed, confirming a role for CYP2C19 in cycloguanil formation in vivo. However, there was substantial overlap of proguanil MRs in subjects of different CYP2C19 genotypes, due possibly to variability in the activity of other enzymes contributing to the formation of cycloguanil.
研究白种人群中氯胍代谢率(MR,氯胍/环氯胍)与CYP2C19基因型之间的关系。
对99名白种人(年龄范围:18 - 55岁,女性54名,男性45名)进行CYP2C19基因分型,并在服用100 mg盐酸氯胍后收集8小时尿液,对氯胍氧化进行表型分析。通过高效液相色谱法测定氯胍和环氯胍浓度。采用聚合酶链反应进行CYP2C19基因分型。
3名(3%)CYP2C19*2纯合子个体(*2/*2)的氯胍MR最高(范围:8.0 - 134.6)。73名(74%)个体为野生型等位基因纯合子(*1/*1),23名(23%)为杂合子(*1/*2)。*1/1个体的MR低于1/*2个体(中位数 = 1.4,范围:0.23 - 5.9,P = 0.003,曼-惠特尼U检验)(中位数 = 2.5,范围:0.88 - 7.3)。
观察到CYP2C19基因剂量对氯胍氧化为环氯胍有影响,证实CYP2C19在体内环氯胍形成中起作用。然而,不同CYP2C19基因型个体的氯胍MR有很大重叠,这可能是由于其他参与环氯胍形成的酶活性存在变异性。